AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock

AbbVie (ABBV) stock has gained 8% in six months, adding over $24 billion in market capitalization, primarily driven by its successful navigation of the Humira patent cliff. The company's new immunology drugs, Skyrizi and Rinvoq, generated $5.1 billion in Q1 2025 sales, up 65%, and are projected to reach over $31 billion by 2027, effectively offsetting declining Humira revenue. Despite ongoing Humira biosimilar erosion and slowing aesthetics sales, AbbVie is bolstering its long-term growth with an attractive pipeline from over 20 recent deals, including an entry into the obesity market, and anticipates returning to robust mid-single-digit revenue growth in 2025 with a high single-digit CAGR through 2029.

Analysis

AbbVie has demonstrated effective management of its Humira patent cliff, a critical risk factor that has now been substantially mitigated. The company's stock appreciation of 8.0% over six months, adding over $24 billion in market value, is directly linked to the robust growth of its next-generation immunology drugs, Skyrizi and Rinvoq. These two assets generated a combined $5.1 billion in Q1 2025, a 65% increase, and are projected to achieve over $31 billion in sales by 2027, successfully offsetting the precipitous decline in Humira revenue, which fell nearly 50% in the same quarter due to biosimilar competition. While the company's ex-Humira platform grew over 21%, significant headwinds persist, notably a 10.2% sales decline in the aesthetics portfolio and ongoing competitive pressure on Imbruvica. To secure future growth, AbbVie is executing an aggressive M&A strategy, with over 20 deals since early 2024 bolstering its pipeline in oncology and neuroscience and marking a strategic entry into the high-growth obesity market. Despite a valuation premium relative to its five-year average (14.21 forward P/E vs. 12.44 mean), upward revisions to 2025 and 2026 earnings estimates support the company's guidance for a return to mid-single-digit revenue growth in 2025 and a high single-digit CAGR through 2029.

Key Decisions for Investors

• Given the successful execution of the post-Humira strategy and a clear growth outlook through 2029, investors may consider the stock a core long-term holding in the pharmaceutical sector.
• Investors should closely monitor the sales momentum of Skyrizi and Rinvoq against company projections, as this performance is the central pillar of the current investment thesis.
• Monitor for a turnaround in the aesthetics portfolio, which saw a 10.2% Q1 sales decline, and watch for key pipeline milestones, such as the new drug application for tavapadon and progress in the recently-entered obesity space, as potential future catalysts.
• While the stock has outperformed, its valuation is not considered cheap, trading above its five-year average P/E, suggesting that entry points should be considered carefully as much of the positive transition may already be reflected in the price.